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Abstract
Pulmonary tumor thrombotic microangiopathy (PTTM) is a fatal disease process in which pulmonary hypertension (PH) develops in
the setting of malignancy. The purpose of this study is to present a detailed analysis of cases of PTTM reported in literature in the
hopes of achieving more ante-mortem diagnoses. We conducted a systematic review of currently published and available cases of
PTTM by searching the term ‘‘pulmonary tumor thrombotic microangiopathy’’ on the Pubmed.gov database. Seventy-nine publi-
cations were included consisting of 160 unique cases of PTTM. The most commonly reported malignancy was gastric adenocar-
cinoma (94 cases, 59%). Cough and dyspnea were reported in 61 (85%) and 102 (94%) cases, respectively. Hypoxemia was
reported in 96 cases (95%). Elevation in D-dimer was noted in 36 cases (95%), presence of anemia in 32 cases (84%), and
thrombocytopenia in 30 cases (77%). Common findings on chest computed tomography (CT) included ground-glass opacities
(GGO) in 28 cases (82%) and nodules in 24 cases (86%). PH on echocardiography was noted in 59 cases (89%) with an average
right ventricular systolic pressure of 71mmHg. Common features of PTTM that are reported across the published literature
include presence of dyspnea and cough, hypoxemia, with abnormal CT findings of GGO, nodules, and mediastinal/hilar lymph-
adenopathy, and PH. PTTM is a universally fatal disease process and this analysis provides a detailed examination of all the available
published data that may help clinicians establish an earlier diagnosis of PTTM.
Keywords
pulmonary hypertension, cancer, embolism, dyspnea
Date received: 17 August 2018; accepted: 3 April 2019
Pulmonary Circulation 2019; 9(2) 1–13
DOI: 10.1177/2045894019851000
Introduction
Pulmonary tumor thrombotic microangiopathy (PTTM) is a
disease process in which tumor cells embolize to the pul-
monary vasculature; there is activation of the coagulation
cascade, formation of ﬁbrin clots, and ﬁbrocellular prolifer-
ation of the intimal layer of blood vessel walls. Elevated
pulmonary artery pressures (PAP) are observed and death
results from right heart failure. PTTM is most commonly
associated with gastric adenocarcinoma but has been
described in numerous other carcinomas.1 In recent years,
PTTM has been reported with increasing frequency. The
pathophysiology is not completely understood and patient
outcomes remain poor with rapid decline in clinical condi-
tion often occurring within weeks of symptom onset.
The purpose of this systematic review is to help achieve
improved rates of ante-mortem diagnosis of PTTM by pre-
senting a comprehensive analysis of patient symptomatol-
ogy, clinical examination ﬁndings, laboratory abnormalities,
radiographic features, pulmonary hypertension (PH), and
histologic observations reported across the published litera-
ture. We also review attempted treatments and clinical out-
come and discuss future directions for research.
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Methods
We conducted a systematic review of currently published
and available cases of PTTM. First, we queried the term
‘‘pulmonary tumor thrombotic microangiopathy’’ on the
Pubmed.gov database in June of 2018 and received 284
search results. After applying ﬁlters for publications in the
English language and those pertaining to humans, 183 items
remained. The University of California library system was
used to access and screen each publication for inclusion for
the systematic review. Articles that pertained to PTTM and
those that presented original data on reported cases of
PTTM were included. Review articles, articles not in the
English language, and inaccessible articles were excluded.
In total, 120 articles were eliminated for the following rea-
sons: the publication was not about PTTM (n¼ 102); the
publication was a reply or comment regarding another pub-
lication (n¼ 8); the article could not be accessed (n¼ 5); and
the publication was a review article (n¼ 4). One publication
was an interactive case based on a publication that was
included (n¼ 1). Sixteen publications were included which
were missed by the queried term but were found by other
means (prior knowledge of the publications or as references
in included publications).
A total of 79 publications were included in the system-
atic review; this included 66 case reports and 13 case
series.1-37,45-92 For each patient described in the publica-
tions, the following information was collected, if available:
age; gender; history of tobacco smoking or alcohol con-
sumption; presence or absence of commonly reported
symptoms (cough, dyspnea, hemoptysis, fatigue, weight
loss, abdominal pain, night sweats, and syncope); signs of
PH and/or right heart failure on examination (jugular
venous distension, loud P2 component of S2 heart sound,
holosystolic murmur at left sternal border, right ventricular
heave, pulsatile liver on palpation, etc.); presence or
absence of hypoxemia (on pulse oximetry or arterial
blood gas analysis); laboratory abnormalities (elevation
of D-dimer and lactate dehydrogenase, anemia, thrombo-
cytopenia, or diagnosis of disseminated intravascular
coagulation [DIC]); abnormal chest radiography; presence
or absence of abnormalities on chest computed tomog-
raphy (CT) (nodules, septal thickening, ground glass opa-
cities [GGO], tree-in-bud opacities, mediastinal or hilar
lymphadenopathy, pleural eﬀusions, and pulmonary
embolism [PE]); elevated right ventricular (RV) pressure
or pulmonary artery pressures (PAP) by two-dimensional
transthoracic echocardiography and/or right heart cath-
eterization (RHC); presence of serum tumor markers or
immunohistochemical staining of ﬁxed tissue specimen
(vascular endothelial growth factor [VEGF]; platelet-
derived growth factor [PDGF]; tissue factor [TF]; 5-
HT2A, serotonin receptor; and osteopontin [OPN]); pres-
ence of characteristic histologic ﬁndings (tumor emboli,
luminal ﬁbrin deposition, ﬁbrocellular intimal hyperpla-
sia); identity of the causative primary malignancy; and
attempted treatment by class of medication. Information
pertaining to the patient’s clinical course was collected,
including whether PTTM was diagnosed ante-mortem or
post-mortem; the duration of time from the diagnosis of
the primary malignancy to the development of PTTM; and
the time to death after the onset of symptoms. Clinical
ﬁndings were logged in a binary fashion (present/absent,
yes/no, etc.). Time was rounded to the nearest half-week or
one-tenth of a year and pulmonary pressures to the nearest
whole number. The frequency of a particular ﬁnding was
calculated based only on ‘‘reporting’’ cases. For example,
27 cases reported a diagnosis of DIC accounting for 48%
of reporting cases because 29 cases (52%) reported an
absence of DIC. A signiﬁcant number of publications did
not include the presence or absence of certain ﬁndings of
PTTM, and thus, were considered ‘‘non-reporting.’’ The
number of ‘‘non-reporting’’ cases is noted when applicable.
Many of the ‘‘non-reporting’’ cases were part of larger retro-
spective autopsy case series, which did not include informa-
tion such as presenting symptoms or physical examination
ﬁndings. Radiographic features of PTTM were compared
between the various primary malignancies and the diﬀerence
in proportions was calculated by the N-1 Chi squared test.
PTTM is compared to its clinical mimic, chronic thrombo-
embolic pulmonary hypertension (CTEPH), in the
‘‘Discussion’’ section. We could not compute any objective
risk of bias though publication bias likely exists.
Results
Seventy-nine publications consisting of 160 patients with
PTTM were studied (Table 1). There were 89 men (56%)
and 71 women (44%). The average patient age was 56 years
(median age¼ 58 years, age range¼ 11–89 years). Twelve
cases had a history of smoking while nine cases did not
(139 cases non-reporting). Gastric adenocarcinoma was
diagnosed in 94 cases (59%), breast cancer in 16 cases
(10%), lung cancer in 10 cases (6.3%), urothelial carcinoma
in six cases (3.8%), and ovarian carcinoma in four cases
(2.5%). The diagnosis of the causative primary malignancy
was made ante-mortem in 57 cases (65%, 72 non-reporting)
and post-mortem in 31 cases (35%). In those cases where
primary malignancy was diagnosed ante-mortem, the aver-
age length of time after the diagnosis of the primary malig-
nancy and before presentation with PTTM is known in 21
cases and is, on average, 3.5 years (median¼ 2 years,
range¼ 0.1–12 years).
Ante-mortem diagnosis of PTTM, in which lung tissue was
available after biopsy, was made in 15 cases (9.4%). On the
other hand, PTTM was diagnosed clinically, without lung
biopsy, in seven cases (4.4%). Most cases of PTTM (n¼ 127;
79%) were diagnosed at the post-mortem examination. The
time from onset of symptoms to death was calculated in
weeks and found to be an average of 9.5 weeks (median¼ 3
weeks; range¼< 0.5–88 weeks; 64 non-reporting cases).
Dyspnea was reported in 102 cases (94%; 52 non-report-
ing) and cough in 61 cases (85%; 88 non-reporting).
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Hypoxemia was reported in 96 cases (95%; 59 non-report-
ing). Table 2 shows the other presenting symptoms of
PTTM.
Abnormal laboratory studies included: elevation in D-
dimer in 36 cases (95%; 122 non-reporting); presence of
anemia in 32 cases (84%; 122 non-reporting); and thrombo-
cytopenia in 30 cases (77%; 121 non-reporting). DIC was
diagnosed in 27 cases (48%; 104 non-reporting).
The chest radiograph was reported to be abnormal in 39
cases (70%; 104 non-reporting). Notable ﬁndings on the chest
CT included: GGO in 28 cases (82%; 126 non-reporting); nod-
ules in 24 cases (86%; 132 non-reporting); mediastinal and/or
hilar lymphadenopathy in 19 cases (91%; 139 non-reporting);
and septal thickening in 17 cases (81%; 139 non-reporting).
In 68 cases, chest CT noted the presence of at least one of
the aforementioned ﬁndings. Table 3 lists the abnormal ﬁnd-
ings on chest CT for each of the three most commonly
reported primary malignancies. In gastric cancer, the most
common ﬁnding on chest CT was mediastinal/hilar lymph-
adenopathy (16/19, 84%). Table 4 outlines the diﬀerences in
CT chest features between gastric cancer and breast, lung,
and all other non-gastric cancers. There is a statistically sig-
niﬁcant diﬀerence in the frequency with which septal
thickening is reported between gastric cancer and breast
cancer (P¼ 0.02, 95% conﬁdence interval [CI]¼ 6.08–86.6)
as well as gastric cancer and all non-gastric cancers
(P¼ 0.05, 95% CI¼ 0.164–66.0). Sensitivity and speciﬁcity
of each CT ﬁnding that would indicate PTTM from gastric
cancer is noted in Table 5. Septal thickening, nodules, and
mediastinal/hilar lymphadenopathy have a sensitivity of
92%, 93%, and 100% and speciﬁcity of 38%, 23%, and
40%, respectively, for the diagnosis of PTTM due to gastric
cancer.
PH, as assessed by transthoracic echocardiography
(TTE), was reported in 59 cases (89%; 94 non-reporting).
The average right ventricular systolic pressure (RVSP) or
pulmonary artery systolic pressure (PASP) on TTE was
71mmHg (median¼ 68mmHg, range¼ 34–140mmHg).
RHC data are available from 22 cases. The average values
(median, range) are as follows: mean pulmonary arterial
pressure (mPAP) of 48mmHg (median¼ 48mmHg,
range¼ 34–70mmHg); pulmonary vascular resistance
(PVR) of 13 Wood units (median¼ 12 WU, range¼ 4–23
WU); pulmonary capillary wedge pressure (PCWP) of
15mmHg (median¼ 12mmHg, range¼ 6–35mmHg); car-
diac output of 3.8 L/min (median¼ 4L/min, range¼ 2–
6.5L/min); and cardiac index of 2.0 L/min/m2
Table 2. Demographics, presenting symptoms, and primary
malignancy.
n (%)
Age, years (mean) 56
Gender
Men 89 (56)
Women 71 (44)
Risk factors for malignancy
Tobacco smoking 9 (57)
Alcohol use 2 (50)
Symptoms
Cough 61 (85)
Dyspnea 102 (94)
Hemoptysis 9 (23)
Fatigue 11 (73)
Weight loss 10 (59)
Abdominal pain 11 (86)
Night sweats 5 (42)
Syncope 6 (43)
Hypoxemia 96 (95)
Primary malignancy
Gastric 94 (59)
Breast 16 (10)
Lung 10 (6)
Urothelial 6 (4)
Unknown 4 (3)
Ovarian 4 (3)
Pancreatic 3 (2)
Esophageal 3 (2)
Prostate 2 (1)
Colon 2 (1)
Gallbladder 2 (1)
Hepatocellular, dual parotid gland/salivary duct,
dual hepatocellular/cholangiocarcinoma,
dual gastric/duodenal, cholangiocarcinoma,
sphenoid sinus, gastroesophageal junction,
extramammary Paget’s disease, salivary duct,
primary myelodysplastic syndrome,
desmoplastic small round cell tumor, angiosarcoma,
kidney malignant rhabdoid tumor,
renal papillary carcinoma
1 (1)
Percentages are calculated based on all the ‘‘reporting’’ cases. See references
1-37 and 46-92 for case reports and series of PTTM.
n, number of cases.
Table 1. Search results, inclusion, and exclusion.
Total search results 284
Filters for English language and human studies 183
Included 79
- Case reports 66
- Case series 13
Excluded
- Not about PTTM 102
- Reply to another article 8
- No access 5
- Review article 4
- Duplicate 1
Articles included but not found through PubMed 16
Pulmonary Circulation Volume 9 Number 2 | 3
(median¼ 2.0L/min/m2, range¼ 1.3–3.2 L/min/m2). In
total, three patients had a PCWP> 15mmHg, while the
rest had pre-capillary PH.
The treatments that have been attempted for PTTM are
in the following classes of medications: advanced PH ther-
apy (phosphodiesterase inhibitor, endothelin-receptor
antagonist, prostacyclin analogue, and inhaled nitric
oxide); anti-neoplastic agents; anticoagulants; diuretics;
and corticosteroids (Table 6). Fourteen patients underwent
treatment with advanced PH therapy while 17 patients
received anti-neoplastic agents. Of the 14 that received
advanced PH therapy, 11 (79%) had undergone a RHC.
Of those, some treatment regimens may have extended the
life of patients beyond what was expected, on the order of
months (Table 7).
The serum tumor markers and/or immunohistochemical
staining of tissue associated with PTTM and their frequen-
cies of positive results were as follows: VEGF in 63 cases
(96%; 94 non-reporting); TF in 55 cases (100%; 106 non-
reporting); PDGF in 32 (74%; 117 non-reporting); and
OPN in 30 cases (64%; 113 non-reporting). Lung tissue,
obtained either by biopsy or at autopsy, revealed tumor
emboli and thrombus formation in association with ﬁbro-
cellular intimal proliferation in 117 cases (100.0%; 43 non-
reporting).
Discussion
PTTM is a diﬃcult diagnosis to establish and most cases are
diagnosed post-mortem. Based on unselected autopsy case
Table 4. Comparison of proportions of each radiographic finding between commonly reported malignancies.
Malignancy Comparison GGO Nodules Tree-in-bud
Septal
thickening
Mediastinal/
hilar adenopathy
Infiltrates/
consolidations
Pleural
effusion
Gastric Breast N/A 0.12
(6.41–63.9)
N/A 0.02
(6.08–86.6)
N/A 0.79
(42.5–46.5)
0.52
(32.0–59.6)
Gastric Lung 0.75
(28.5–57.0)
0.09
(3.73–83.9)
1.000
(47.4–47.4)
0.25
(12.0–71.7)
N/A 0.79
(42.5–46.5)
N/A
Gastric Non-gastric 0.10
(4.49–45.6)
0.24
(11.6–43.8)
N/A 0.05
(0.164–66.0)
N/A 0.28
(16.3–52.0)
0.27
(15.8–56.7)
This table illustrates statistical significance of CT findings between different types of malignancies in cases of PTTM. Septal thickening is a radiographic feature that is
statistically more common in gastric cancer than in breast cancer or all non-gastric cancer cases. P values are listed with 95% CIs in parentheses.
Comparison of proportions online calculator was used for this statistical analysis (https://www.medcalc.org/calc/comparison_of_proportions.php)
N/A, comparison of proportions cannot be done in cases if proportion is either 0% or 100%.
Table 3. Common chest CT features of PTTM.
Malignancy GGO (%)
Nodules
(%)
Tree-in-bud
(%)
Septal
thickening (%)
Mediastinal/
hilar adenopathy (%)
Infiltrates/
consolidations (%)
Pleural
effusion (%)
Gastric 10 (36) 14 (58) 6 (55) 12 (71) 16 (84) 7 (47) 5 (38)
Breast 4 (14) 4 (17) 0 (0) 1 (6) 2 (11) 2 (13) 1 (8)
Lung 2 (7) 1 (4) 2 (18) 2 (12) 1 (5) 2 (13) 2 (15)
Total non-gastric 18 (64) 10 (42) 5 (45) 5 (29) 3 (16) 8 (53) 8 (62)
Overall* 28 24 11 17 19 15 13
This table shows radiographic findings and the relative proportions (in parenthesis) of each finding in the three most common primary malignancies reported in
patients with PTTM as well as the total non-gastric cases.
*Overall includes number of cases reporting a particular radiographic finding.
Table 5. Sensitivity and specificity of radiographic findings for gastric cancer versus non-gastric cancers causing PTTM.
GGO Nodules Tree-in-bud Septal thickening
Mediastinal/
hilar adenopathy
Infiltrates/
consolidations Pleural effusion
Sensitivity 75% (10/15) 93% (14/15) 50% (6/12) 92% (12/13) 100% (16/16) 58% (7/12) 56% (5/9)
Specificity 5% (1/19) 23% (3/13) 29% (2/7) 38% (3/8) 40% (2/5) 20% (2/10) 20% (2/10)
This table shows the sensitivity and specificity of each radiographic finding for identification of gastric cancer as the primary malignancy causing PTTM.
GGO, ground-glass opacities.
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series of patients with carcinoma, characteristic histologic
features of PTTM were seen in 1.4% and 3.3% of cases.1,2
Among autopsy cases of gastric cancer alone, features of
PTTM were seen in 16.7% of cases.3 The purpose of this
systematic review is to present an analysis of patient symp-
tomatology, clinical examination ﬁndings, laboratory
abnormalities, radiographic features, PH, and histologic
observations reported across the published literature. The
limitation of this systematic review includes publication
bias as many cases of PTTM may go unpublished, which
may signiﬁcantly aﬀect the results including reported fre-
quencies of ﬁndings presented herein.
Symptoms and physical examination
The symptoms associated with PTTM can easily be attrib-
uted to benign etiologies, potentially leading clinicians away
from establishing an accurate diagnosis. Cough in PTTM is
generally reported as dry, can persist throughout the day,
and gets progressively worse.4–6 Cough can present as early
as a year before presentation or late in the course of the
disease.7–12 Absence of cough has also been noted.13,14
The exact mechanism of cough is not completely under-
stood, but in two cases of PTTM, the initiation of chemo-
therapy alleviated it, suggesting a mechanism that involves
tumor inﬁltration of airway mucosa and stimulation of
cough receptors.6,15,16
Dyspnea is frequently noted to be progressive and insidi-
ous. Exertional dyspnea generally progressed to resting dys-
pnea.5,7,17 Dyspnea may be subacute, with onset months
before presentation, or may be rapidly progressive, with
one patient being able to run a half-marathon two months
before presentation but who could not climb a ﬂight of stairs
at presentation.13,14 Dyspnea on exertion is sometimes pre-
sent along with the symptoms of orthopnea and paroxysmal
nocturnal dyspnea and examination ﬁndings of jugular
venous distension and lower extremity edema.18 Cough
can be followed by progressively worsening dyspnea or it
can start after the onset of dyspnea.7,18 The pathophysiology
of dyspnea, which is sometimes noted to occur with malaise,
may be due to PH resulting in increased RV afterload,
reduced RV cardiac output, and hypoxemia. Exaggerated
pulsus paradoxus from a dilated RV and reduction in left
ventricular output may also be a contributing factor.
Dyspnea as a result of airﬂow obstruction, especially
during episodes of cough, is also a possible mechanism.16
Although cough and dyspnea are the most commonly
reported symptoms, other symptoms may provide a clue
as to the origin of the primary malignancy. While gastric
cancer can present with a paucity of symptoms, symptoms
such abdominal pain and weight loss may be due to gastric
adenocarcinoma, the most commonly reported malignancy
associated with PTTM.
Hypoxemia
Patients with PTTM will nearly invariably develop hypox-
emia. Most, but not all patients, present to the hospital with
some degree of hypoxemia. Patients who presented with sig-
niﬁcant hypoxemia requiring supplemental oxygen survived
only days or a few weeks after presentation.14,19 Hypoxemia
was noted upon exertion during a 6-min walk test in one
case, which worsened over the course of a few days to hyp-
oxemia at rest.7 Progression can be even more rapid: one
patient with normal oxygen saturation of 96% at presenta-
tion developed hypoxemia within one day and subsequent
cardiac arrest within three days of presentation.9 There was
presence of jugular venous distension, loud P2 component
of the S2 heart sound, gallop S3 heart sound, and/or RV
heave in 10 cases implying heart failure and PH. Reduction
in RV cardiac output due to severe PH and volume/pressure
overload, reduction in LV cardiac output, increased shunt-
ing, tumor inﬁltration of the alveolar lining, and impairment
of gas diﬀusion across the capillary membrane may be the
mechanisms of hypoxemia. The degree of hypoxemia is
likely related to the extent of metastatic disease aﬀecting
gas exchange, the degree of shunting, and the severity of
PH aﬀecting RV cardiac output. Treatment of both the
malignancy as well as the underlying vasculopathy may
help prevent acute decompensation of the RV and help pre-
vent worsening hypoxemia and respiratory failure.
Laboratory abnormalities
The most common abnormalities in laboratory analysis
include elevation of D-dimer, presence of anemia, develop-
ment of thrombocytopenia, and elevation of LDH. It has
Table 6. Medications used previous in PTTM.
Medication class Medication name Cases (n)
Advanced PH therapy Sildenafil
Tadalafil
Ambrisentan
Bosentan
Epoprostanol
14
Anti-neoplastic drugs Imatinib
TS-1 chemo
Irinotecan
S-1 (tegafur,
gemaricil, oteracil)
5-Fluorouracil
Cisplatin
Nedaplatin
Capecitabine
Oxaliplatin
Epirubicin
17
Diuretics Furosemide
Spironolactone
6
Corticosteroids Dexamethasone
Prednisone
16
Anticoagulation Warfarin 15
Pulmonary Circulation Volume 9 Number 2 | 5
T
a
b
le
7
.
T
re
at
m
e
n
t
an
d
o
u
tc
o
m
e
s.
P
u
b
lic
at
io
n
(r
e
fe
re
n
ce
)
m
PA
P
(S
/D
)
b
e
fo
re
th
e
ra
py
(m
m
H
g)
m
PA
P
(S
/D
)
af
te
r
th
e
ra
py
(m
m
H
g)
C
I
b
e
fo
re
th
e
ra
py
(L
/m
in
/m
2
)
C
I
af
te
r
th
e
ra
py
(L
/m
in
/m
2
)
P
ri
m
ar
y
m
al
ig
n
an
cy
T
h
e
ra
py
Su
rv
iv
al
(m
o
n
th
s)
Pu
bl
ic
at
io
ns
sh
ow
in
g
im
p
ro
ve
m
en
t
in
PH
an
d
su
rv
iv
al
Fu
k
ad
a
e
t
al
.3
3
6
0
(9
3
/3
9
)
5
0
(8
7
/3
0
)
1
.6
3
2
.8
3
B
re
as
t
ad
e
n
o
ca
rc
in
o
m
a
Im
at
in
ib
(2
0
0
m
g/
d
*)
,
ta
d
al
af
il
4
0
m
g
1
–
g
H
ig
o
e
t
al
.1
5
4
8
(7
7
/3
1
)
3
5
(6
9
/1
7
)
1
.8
2
4
.6
4
C
o
lo
n
ad
e
n
o
ca
rc
in
o
m
a
Im
at
in
ib
(5
0
m
g/
d
ay
y )
,
b
e
va
ci
zu
m
ab
(5
m
g/
k
g)
,
S-
1
z
(1
0
0
m
g/
d
ay
)
1
2
K
u
b
o
ta
e
t
al
.3
2
4
6
(7
0
/3
1
)
2
2
(3
5
/1
2
)
N
A
N
A
G
as
tr
ic
ad
e
n
o
ca
rc
in
o
m
a
Im
at
in
ib
(2
0
0
m
g/
d
),
b
o
se
n
ta
n
(6
2
.5
m
g)
,
ta
d
al
af
il
(4
0
m
g)
,
T
S-
1
,
o
x
al
ip
la
ti
n
7
O
ga
w
a
e
t
al
.3
1
**

4
7

2
3

2

4
G
as
tr
ic
an
d
d
u
o
d
e
n
al
ad
e
n
o
ca
rc
in
o
m
as
B
o
se
n
ta
n
,
e
p
o
p
ro
st
an
o
l
(3
.8
n
g/
k
g/
m
in
)
ca
te
ch
o
la
m
in
e
s,
im
at
in
ib
(1
0
0
m
g/
d
),
T
S-
1
1
0
M
in
at
su
k
i
e
t
al
.3
0
4
8
1
3
2
.6
9
2
.7
1
G
as
tr
ic
ad
e
n
o
ca
rc
in
o
m
a
Im
at
in
ib
(2
0
0
m
g/
d
),
ta
d
al
af
il
(2
0
m
g)
,
si
ld
e
n
af
il
(6
0
m
g)
,
am
b
ri
se
n
ta
n
(1
0
m
g)
1
3
Pu
bl
ic
at
io
ns
sh
ow
in
g
im
p
ro
ve
d
su
rv
iv
al
w
ith
ou
t
in
fo
rm
at
io
n
re
ga
rd
in
g
PH
M
iy
an
o
e
t
al
.1
0
N
A
N
A
N
A
N
A
G
as
tr
ic
ad
e
n
o
ca
rc
in
o
m
a
S-
1
,
d
e
x
am
e
th
as
o
n
e
,
w
ar
fa
ri
n
,
as
p
ir
in
7
yy
K
ay
at
an
i
e
t
al
.6
N
A
N
A
N
A
N
A
A
d
e
n
o
ca
rc
in
o
m
a
o
f
u
n
k
n
o
w
n
o
ri
gi
n
S-
1
,
ci
sp
la
ti
n
,
S-
1
,
ge
m
ci
ta
b
in
e
1
0
m
o
n
th
s
la
te
r
w
it
h
re
cu
rr
e
n
ce
o
f
sy
m
p
to
m
s
1
5
Pu
bl
ic
at
io
ns
sh
ow
in
g
no
im
p
ro
ve
m
en
t
in
PH
w
ith
as
so
ci
at
ed
su
rv
iv
al
P
u
rg
a
e
t
al
.3
4
3
7
(6
4
/2
2
)
3
8
(7
0
/2
2
)
1
.7
2
.0
O
va
ri
an
ad
e
n
o
ca
rc
in
o
m
a
iN
O
,
d
o
b
u
ta
m
in
e
,
d
o
p
am
in
e
,
va
so
p
re
ss
in
,
tr
e
p
ro
st
in
il
1
E
n
d
ic
o
tt
-Y
az
d
an
i
e
t
al
.4
5
3
7
(7
0
/3
0
)
N
A
(w
o
rs
e
n
in
g
P
H
b
u
t
p
re
ss
u
re
s
n
o
t
re
p
o
rt
e
d
)
N
A
N
A
G
as
tr
ic
ad
e
n
o
ca
rc
in
o
m
a
E
p
o
p
ro
st
an
o
l
2
.5
*A
d
m
in
is
te
re
d
as
p
ar
t
o
f
a
cl
in
ic
al
tr
ia
l
w
it
h
ap
p
ro
va
l
fr
o
m
th
e
in
st
it
u
ti
o
n
al
re
vi
ew
b
o
ar
d
.
Im
at
in
ib
d
o
se
w
as
in
cr
e
as
e
d
to
4
0
0
m
g
af
te
r
re
d
u
ct
io
n
in
PA
P.
yIm
at
in
ib
st
ar
te
d
at
5
0
m
g/
d
ay
an
d
gr
ad
u
al
ly
in
cr
e
as
e
d
to
2
0
0
m
g/
d
ay
.
zS
-1
co
n
si
st
s
o
f
te
ga
fu
r,
gi
m
e
ra
ci
l,
an
d
o
te
ra
ci
l
p
o
ta
ss
iu
m
.
**
M
e
as
u
re
m
e
n
ts
ar
e
e
st
im
at
e
s
b
e
ca
u
se
th
ey
w
e
re
e
x
tr
ap
o
la
te
d
fr
o
m
a
gr
ap
h
an
d
va
lu
e
s
o
f
m
PA
P
an
d
C
I
w
e
re
n
o
t
e
x
p
lic
it
ly
st
at
e
d
yy
P
H
w
as
n
o
t
p
re
se
n
t
in
th
is
ca
se
o
n
e
ch
o
ca
rd
io
gr
ap
h
y
b
u
t
it
is
u
n
cl
e
ar
w
h
e
n
d
u
ri
n
g
th
e
p
at
ie
n
t’
s
cl
in
ic
al
co
u
rs
e
th
e
e
ch
o
ca
rd
io
gr
ap
h
y
w
as
p
e
rf
o
rm
e
d
.
T
h
e
p
at
ie
n
t
w
as
fo
llo
w
e
d
fo
r
se
ve
n
m
o
n
th
s,
at
w
h
ic
h
ti
m
e
sh
e
w
as
d
o
in
g
w
e
ll
b
u
t
n
o
fu
rt
h
e
r
fo
llo
w
-u
p
w
as
p
u
b
lis
h
e
d
.
C
I,
ca
rd
ia
c
in
d
e
x
;
iN
O
,
in
h
al
e
d
n
it
ri
c
o
x
id
e
;
m
PA
P,
m
e
an
p
u
lm
o
n
ar
y
ar
te
ry
p
re
ss
u
re
;
N
A
,
n
o
t
av
ai
la
b
le
;
S/
D
,
sy
st
o
lic
/d
ia
st
o
lic
;
T
S-
1
,
ti
ta
n
iu
m
si
lic
at
e
1
.
6 | A Systematic Review Godbole et al.
been hypothesized that tumor cell embolization to pulmon-
ary arterioles induces the activation of coagulation, platelet
aggregation, and release of various cytokines derived from
platelets, tumor cells, and endothelial cells including PDGF
and VEGF.1,20
Anemia and elevation in the LDH may be a result of
shearing of erythrocytes passing through the pulmonary cir-
culation.1 Thrombocytopenia may be due to increased con-
sumption from DIC, increased sequestration, reduced
production due to tumor cell inﬁltration of the bone
marrow, or an unknown mechanism related to acute critical
illness. Elevated D-dimer is most likely due to the activation
of coagulation cascade, aggregation of platelets, and subse-
quent breakdown of ﬁbrinogen into ﬁbrin degradation
products.20 The aforementioned laboratory abnormalities
develop over time and thus it is possible that a patient
with underlying PTTM may not have any laboratory
abnormalities or may present with a singular salient abnor-
mality such as an anemia or elevation in LDH or D-dimer.21
A signiﬁcant number of patients (27 cases; 48%) noted the
development of DIC. Carcinomas are known to be a pro-
voking factor for the development of DIC.22
The time course of the development of the aforemen-
tioned laboratory abnormalities potentially informs the clin-
ician of the aggressiveness of the underlying malignancy as
well as the severity of the vasculopathy, including occlusion
of vasculature by tumor emboli, damage to endothelium,
activation of the coagulation system, and formation of
ﬁbrin strands causing hemolysis.1
Radiographic features
The chest radiograph was reported abnormal in 70% of the
cases. Speciﬁc ﬁndings on the chest radiograph were not
recorded due to the signiﬁcant variation in the description
of the abnormalities. In addition, chest radiographic ﬁnd-
ings were not reported in 104 cases. It is reasonable to say
that the main purpose of the chest radiograph is to expedite
further testing including a chest CT and echocardiogram. In
circumstances where the radiograph is normal, a high index
of clinical suspicion would be required to prompt additional
studies.23 In the case of normal chest radiography, non-
resolving or progressive symptoms and hypoxemia should
prompt an expedited work-up.
The chest CT commonly revealed features of GGO, nod-
ules, septal thickening, mediastinal/hilar lymphadenopathy,
and consolidation (Tables 3–5). The ground-glass opaciﬁca-
tion may reﬂect tumor inﬁltration of alveolar septae.24
Nodules are generally seen in a centrilobular distribution
and are most likely to result from hematogenous spread
of malignancy through pulmonary arterioles.19 The histo-
logic correlate of septal thickening is understood to be
engorgement of lymphatic channels.19 While some studies
have previously reported pulmonary venular involvement,
the radiographic correlates speciﬁc to pulmonary ven-
ules are unknown.19,25 Finally, mediastinal and hilar
lymphadenopathy probably results from drainage of
tumor cells via interlobular lymphatic channels or drainage
via the thoracic duct in gastric cancer.
The metastatic spread of the primary malignancy,
whether by hematogenous or lymphatic means, likely inﬂu-
ences the radiographic features seen in PTTM. There is con-
siderable overlap in the radiographic features and source of
the primary cancer. However, we noted that there was a
signiﬁcant diﬀerence in the proportion of patients with
septal thickening who also harbored gastric cancer versus
breast cancer and versus all non-gastric cancer. These ﬁnd-
ings should be interpreted with caution as they are based on
a small number of patients. As more cases are reported, the
presence and absence of commonly reported CT ﬁndings
should be published to help improve the distinction between
radiographic features in PTTM due to diﬀerent primary
malignancies.
We also calculated the sensitivity and speciﬁcity of each
CT feature for gastric cancer as the underlying primary
malignancy causing PTTM given the larger number of
reported cases in the literature. Septal thickening, nodules,
and mediastinal/hilar lymphadenopathy have high sensitiv-
ity but low speciﬁcity. Again, the results should be inter-
preted with caution because of the considerable
publication bias which likely skews the data towards the
presence of certain CT ﬁndings rather than their absence.
Thus, both sensitivity and speciﬁcity could be signiﬁcantly
higher or lower than what is reported here.
The use of 18-ﬂuoro-deoxyglucose (FDG) positron emis-
sion tomography (PET) and ventilation-perfusion (V/Q)
scans for the diagnosis of PTTM has been limited.19,20
One case reported seeing evidence of FDG uptake suggest-
ive of metastatic cancer though the primary malignancy
could not be identiﬁed (at autopsy, the primary malignancy
was discovered to be in the stomach).26 One case reported
wedge-shaped defects on perfusion scanning of the lung in a
patient with PTTM.27
Pulmonary hypertension
PH due to PTTM most likely occurs as a result of luminal
occlusion by tumor cells, ﬁbrin deposition, and ﬁbrocellular
intimal hyperplasia, thus increasing PVR. The degree of
stenosis of vessels and how widespread the vasculopathy is
throughout the lungs may inﬂuence the severity of the PH.28
In the World Health Organization (WHO) classiﬁcation
system, PTTM ﬁts under the miscellaneous Group 5 PH
category.20,29 At the time of presentation to the hospital,
10 cases noted an abnormal physical examination with
signs of volume overload including jugular venous disten-
sion and lower extremity edema as well as ﬁxed splitting of
S2 heart sound with a loud P2 component, indicating PH.
An echocardiogram is indicated as soon as possible to iden-
tify PH and the degree of RV dysfunction. In our prior
analysis of seven cases of PTTM, the echocardiogram was
obtained an average of nine days after the initial clinical
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presentation (range¼ 1–28 days, median¼ 5 days). The two
patients with the greatest delays, 17 and 28 days, had pre-
sented in the outpatient setting (unpublished data).
The rapidity of progression is most probably related to
the ability of the right ventricle to compensate for the pres-
sure and/or volume overload. In one patient whose dyspnea
began two months before presentation, the echocardiogram
showed a dilated right ventricle but no compensatory hyper-
trophy and with a PASP of 75mmHg.14 In many cases, a
RHC is not done due to rapid clinical decline.
In this analysis, there were 22 patients that underwent a
RHC; among them, 11 were started on advanced PH medi-
cations and ﬁve on anti-neoplastic medications. We noted
ﬁve cases in which a RHC documented improvement in the
mPAP (Table 7). In four of those cases, the mean survival
was 10.5 months (median¼ 11 months, range¼ 7–13
months). These ﬁndings do raise the question of whether
early initiation of treatment to ameliorate the right ventricu-
lar pressure and volume overload could increase survival.
RHC may be useful in several contexts. First, it allows for
an assessment of hemodynamics, especially when physical
examination or echocardiography is ambiguous. Second, it
may guide initiation of advanced PH therapy (e.g. endothe-
lin receptor antagonists, prostacyclin analogues), diuresis,
inotropic support, and even anti-neoplastic drugs.30,31 In
ﬁve particular cases (Table 7) of PTTM where imatinib
was administered, there was an improvement in the mPAP
in each case and improvement in survival in four out of ﬁve
patients compared to what is normally expected with
PTTM.15,30,32,33 In one of these cases, anti-neoplastic
drugs imatinib and bevacizumab were administered without
advanced PH medications and yet the patient survived for
12 months.15 Another patient suﬀering from ovarian cancer
received advanced PH therapy with inhaled nitric oxide and
intravenous treprostinil without anti-neoplastic agents and
her condition deteriorated over one month.34 This raises the
question that anti-neoplastic agents are potentially eﬃca-
cious and adjunct PH therapy may be important.
Prospective trials will be needed to help clarify treatment
options in PTTM. Imatinib speciﬁcally is discussed later.
Finally, RHC may allow for sampling of blood from the
pulmonary artery, which in some cases reveals the presence
of tumor cells, allowing for a diagnosis of the primary
malignancy and/or tumor emboli.35 RHC need not always
be pursued, especially if there is suﬃcient evidence, based on
the overall clinical picture, to suspect a diagnosis of PTTM.
Lung histology, immunohistochemistry, and
serum tumor markers
In the literature, lung histology has consistently revealed
tumor cells within the lumen of pulmonary pre-capillary
vessels, with surrounding ﬁbrin deposition along with ﬁbro-
cellular intimal hyperplasia. One publication studied the
degree of stenosis of pulmonary pre-capillary vessels
among six autopsy cases of PTTM. There was an inverse
relationship between vessel diameter and the degree of sten-
osis. PH was assessed only in two cases and there appeared
to be a correlation between PH and the degree of stenosis as
well as how diﬀuse the vasculopathy was throughout the
lung.28 Pulmonary venular and lymphatic involvement
have also been documented in the literature.1,19,25
Immunohistochemical staining revealed tumor cells stain-
ing positively for PDGF, VEGF, TF, and OPN. The patho-
physiology of PTTM involves a complex interplay between
tumor cells, endothelial cells, smooth muscle cells, inﬂam-
matory cells, mediators of inﬂammation (PDGF and VEGF
released by tumor cells) and tissue repair (OPN released by
tumor cells, macrophages, and ﬁbrointimal cells), and acti-
vators of the coagulation system (TF released by tumor cells
and endothelial cells).20,35,36 Upon the embolization of
tumor cells into pulmonary vasculature, endothelial injury
releases TF which initiates the coagulation cascade and for-
mation of ﬁbrin clots. Platelet aggregation occurs and plate-
lets release cytokines and chemokines, including PDGF,
which attract macrophages to the area of inﬂammation.20
Tumor cells also release PDGF and VEGF which stimulates
ﬁbrocellular intimal thickening and angiogenesis.20 PDGF
upregulates the production of OPN, a glycoprotein, that is
released at sites of endothelial damage and inﬂammation,
and may be involved in vascular remodeling.35 VEGF pro-
motes the cleavage of OPN, creating fragments that act as a
chemoattractant for smooth muscle cells, suggesting a role
in smooth muscle cell proliferation and angiogenesis.35,37,38
PDGF and VEGF levels have been measured in the
serum. Their role in clinical care will likely not be in the
diagnosis of PTTM but rather in assessing response to treat-
ment.30,31 One case report demonstrated a decrease in the
PDGF level from about 3000 pg/mL to< 500 pg/mL within
30 days after the initiation of imatinib.31 In another case
report, a decrease in VEGF levels from 240 pg/mL to
15.6 pg/mL was seen after treatment with dexamethasone,
warfarin, aspirin, and S-1 chemotherapy.10
Clinical mimic
The two diseases, CTEPH and PTTM, share some simila-
rities but there are signiﬁcant diﬀerences. In both entities, a
high index of clinical suspicion is required to make the diag-
nosis. Symptomatically, both conditions may present with
dyspnea. However, cough is a common symptom in PTTM
but is less common in CTEPH.40 CTEPH generally pro-
gresses over longer periods of time while PTTM progresses
over a few weeks.41 Both CTEPH and PTTM may present
with features of PH and right heart failure on physical
examination.40 Other signiﬁcant diﬀerences exist (see
Table 8).
In PTTM, a chest radiograph may reveal reticulations
and multiple pulmonary nodules; in CTEPH, there is car-
diomegaly, dilatation of the right descending pulmonary
artery, and opaciﬁed areas representing pulmonary infarc-
tion.40 High-resolution CT scans may be able to diﬀerentiate
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PTTM from CTEPH. In CTEPH, CT scanning often reveals
diﬀuse mosaicism, wedge-shaped opacities (sometimes con-
taining central cavitation) representing prior infarction, and
prominence of the bronchial artery circulation.40 In con-
trast, PTTM lacks all of the aforementioned features on
chest CT with the most common ﬁndings described previ-
ously. V/Q scans may be abnormal in PTTM as well as
CTEPH; however, in general, there is a paucity of data
regarding the role of the V/Q scan in the diagnosis of
PTTM. As such, the use of V/Q scan is unlikely to diﬀeren-
tiate CTEPH and PTTM.
Hemodynamic assessment with echocardiography and
RHC are appropriate in both conditions but unlikely to
distinguish the two diseases.
The pathobiology of CTEPH includes thromboemboli,
along with ﬁbrocellular intimal proliferation, which is simi-
lar to that of PTTM.42 In PTTM, nests of tumor cells may
also be seen within the thrombus. The hypothesized patho-
physiology of PTTM is diﬀerent than CTEPH in that it
includes the release of various molecules such as VEGF,
PDGF, and OPN directly by the tumor cells.20
Interestingly, in large prospective registry data, 12.7% of
patients with CTEPH also had a history of cancer.41 This
registry data did not include histologic analysis of lung
tissue from patients with CTEPH. However, in a manuscript
dedicated to examining the histopathology of CTEPH,
including lung biopsies (n¼ 15) and autopsies (n¼ 16),
there was no mention of the presence of tumor cells within
the pulmonary vasculature.43 In a case series of patients that
underwent surgical thromboendarterectomy, tumor cells
were not identiﬁed however the authors state that neoplastic
embolic PH should be in the diﬀerential diagnosis of cases of
chronic thromboemboli.44
At present time, the aforementioned diﬀerences in clinical
progression, the radiographic ﬁndings by high-resolution
CT chest, and the histopathology demonstrating tumor
cells within vessel lumen/wall and thrombi are the features
which likely best distinguish PTTM from CTEPH. Though
lung biopsy may help to diﬀerentiate CTEPH in patients
with a history of cancer and PTTM, given the tenuous clin-
ical status of such patients and high peri-operative risk of
complications, obtaining lung biopsy is not recommended.
Treatment
A number of treatments have been attempted for patients
diagnosed with or suspected of having PTTM. The chal-
lenge remains the low rate of ante-mortem diagnoses.
While the average time to death from the onset of symptoms
is approximately 9.5 weeks, a handful of publications do
Table 8. Comparing clinical mimics CTEPH and PTTM.
CTEPH PTTM
Clinical presentation
Clinical progression Chronic Acute to subacute
Dyspnea* Common Common
Cough* Less common Common
Radiographic features
Chest CTy Mosaicism
Wedge-shaped infarcts
Prominence of bronchial artery circulation
Ground-glass opacities
Nodules
Mediastinal/hilar adenopathy
Septal thickening
Hemodynamicsz
mPAP,mmHg (median) 47 (n¼ 669) 48 (n¼ 20)
PCWP, mmHg (median) – 12 (n¼ 14)
PVR, dynes*s*cm5 (median) 709 (n¼ 604) 928 (n¼ 9)
Cardiac index, L/min/m2 (median) 2.2 (n¼ 632) 2 (n¼ 8)
Histopathology§
Thromboemboli Y Y
Fibrocellular intimal proliferation Y Y
Involvement of pulmonary arterioles Y Y
Involvement of pulmonary venules Y Y
Presence of tumor cells N Y
*Symptoms of dyspnea can be seen in both; while cough is atypical in CTEPH, it is commonly noted in PTTM. Absence of these symptoms does not preclude either
of the two disease entities.
yRadiographic information regarding CTEPH obtained from Gopalan et al.40 Radiographic features of PTTM obtained from review of all cases included in this
systematic review with radiographic information available.
zHemodynamic data obtained from Pepke-Zaba et al. CTEPH prospective international registry.43
§Histopathology information regarding CTEPH obtained from Lang et al.42
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report survival that is longer than what is expected with the
natural progression of PTTM (Table 7). Among the import-
ant factors leading to a longer survival may be that the
treatment regimen results in improvement in pulmonary
pressures and/or cardiac output, in addition to treatment
of the malignancy. One case report documented an improve-
ment in mPAP from 48mmHg to 34mmHg after 16 days of
treatment with imatinib, sildenaﬁl, ambrisentan, total gas-
trectomy, and TS-1 chemotherapy (treatments were initiated
at diﬀerent time courses) with an eventual reduction in
mPAP to 13mmHg at four months.30 In another case,
after the initiation of treatment, there was an improvement
in mPAP from 47mmHg to 40mmHg after 30 days, down
to mid-20mmHg after 90 days.31
Though selected reports have shown improvement in sur-
vival with the use of imatinib, there are reports of longer
than expected survival without the administration of imati-
nib. In the ﬁrst case, the patient received S-1 chemotherapy
and cisplatin and survived 15 months after diagnosis.6 In the
second case, the patient received S-1 chemotherapy, aspirin,
warfarin, and dexamethasone and survived for at least seven
months though further follow-up is not reported.10
Imatinib, as a PDGF receptor inhibitor, may have a role
in reducing the vascular remodeling that promulgates PH.
While it has shown promise by prolonging survival in some
cases, its role may be limited to various factors including the
type of primary malignancy; any further use ought to be
studied more extensively.20 Bevacizumab, a VEGF receptor
inhibitor, has also been used in one case in conjunction with
S-1 chemotherapy and imatinib—where the patient experi-
enced a survival of 12 months after a diagnosis of PTTM.15
With the appropriate approval of institutional review
boards, future studies aimed at improving survival in
PTTM should be undertaken. Improved understanding of
the pathobiology of the disease process may help generate
more eﬃcacious therapeutic targets.
Future directions
The prevalence of PTTM in autopsy case series of carcin-
oma is estimated at 1.4% in one report and 3.3% in
another.1,2 In a gastric cancer autopsy case series, PTTM
was found in 16.7% of cases.3 However, the true prevalence
is unknown. Studies assessing for PH in patients with malig-
nancy may provide an opportunity to understand the true
prevalence and burden of this disease process. From our
experience and the experience of others, the tumor emboli
and resulting vasculopathy is not a diﬀuse process but rather
the extent of pulmonary vascular stenosis appears to be het-
erogeneous.28 Therefore, there may only be patchy ﬁndings
on chest CT. We encourage clinicians to provide more
detailed descriptions of the radiographic features and to
describe the evolution of these features over time to better
understand the evolution of the disease process. The loca-
tion or distribution of nodules and ground-glass opaciﬁca-
tion (e.g. conﬁned to one lobe, random versus centrilobular)
and the extent of septal thickening (whether localized or
encompassing multiple lobes of the lung) should be speci-
ﬁed. A more quantitative analysis of the presence, distribu-
tion, and extent of the common radiographic features would
be of signiﬁcant value. In addition, we urge clinicians to
consider elaborating on the assessment of PH, especially
data gathered from the RHC, and, if available, hemo-
dynamic assessment before and after the initiation of treat-
ment. With continued improvement in our understanding of
the pathobiology, we may yet identify new factors involved
in the complex web of interactions that leads to the devel-
opment of PH in PTTM.
Conclusion
PTTM is a clinicopathologic disease process with an extre-
mely poor prognosis. This analysis provides a detailed
examination of all the available published data that may
help clinicians establish an earlier diagnosis of PTTM. The
information contained herein will also hopefully allow pro-
viders to consider treatment options, in the context of clin-
ical trials, in order to improve survival in this universally
fatal disease process.
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